Rate Video

ASCO 2015 | Results of the phase 2 trial of daratumumab in multiple myeloma

Joseph Mikhael • 2 Jun 2015

ASCO 2015

Multiple Myeloma Daratumumab

Dr Joseph Mikhael, at ASCO 2015, discusses the results of the phase 2 study of daratumumab in patients with 3 or more lines of prior therapy, or double refractory multiple myeloma.

Advances in monoclonal antibody therapy for multiple myeloma

Joseph Mikhael • 11 Apr 2015

Why research institutes should use social media

Joseph Mikhael • 3 Dec 2016

Mentorship in the virtual era

Joseph Mikhael • 21 Oct 2020

Where do new drugs fit into the treatment landscape of multiple myeloma?

Related Videos

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

Managing CRS in myeloma

Managing transplant patients during the COVID-19 pandemic

Christian Chabannon

DNA methyltransferase inhibitors: daratumumab enhancement for MM